Statins, bone formation and osteoporosis: Hope or hype?

Hormones

Volumn 11, Issue 2, 2012, Pages 126-139

  Tsartsalis, Athanasios N ^a,b   Dokos, Charalambos ^c   Kaiafa, Georgia D ^c   Tsartsalis, Dimitris N ^d   Kattamis, Antonios ^b   Hatzitolios, Apostolos I ^c,e   Savopoulos, Christos G ^c,e  

^a WHITTINGTON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ATHENS   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d HIPPOKRATION HOSPITAL   (Greece)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Adipogenesis; Bone formation; Bone mineral density; OPG; Osteoporosis; RANKL; Statins

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SIMVASTATIN;

ADIPOGENESIS; BONE DENSITY; BONE DEVELOPMENT; BONE METABOLISM; DRUG EFFECT; DRUG MECHANISM; EXPERIMENTAL STUDY; FRACTURE; HUMAN; META ANALYSIS (TOPIC); NONHUMAN; OBSERVATIONAL STUDY; OSSIFICATION; OSTEOPOROSIS; PLEIOTROPY; REVIEW; SYSTEMATIC REVIEW;

EID: 84863465694     PISSN: 11093099     EISSN: None     Source Type: Journal    
DOI: 10.14310/horm.2002.1339     Document Type: Review

References (72)

1. Data from the World Health Organization Assessment of osteoporosis at the primary health care level. Summary report of a WHO scientific Group 2007; WHO, Geneva.
2. Cole ZA, Dennison EM, Cooper C, 2008 Osteoporosis epidemiology update. Curr Rheumatol Rep 10: 92-96.
3. Nguyen ND, Ahlborg HG, Center JR, Eisman JA, Nguyen TV, 2007 Residual lifetime risk of fractures in women and men. J Bone Miner Res 22: 781-788.
4. Pinheiro MM, Reis Neto ET, Machado FS, et al, 2010 Risk factors for osteoporotic fractures and low bone density in pre and postmenopausal women. Rev Saude Publica 44: 479-485.
5. Painter SE, Kleerekoper M, Camacho PM, 2006 Secondary osteoporosis: a review of the recent evidence. Endocr Pract 12: 436-445.
6. Vega D, Maalouf NM, Sakhaee K, 2007 Clinical review: the role of receptor activator of nuclear factor kappa B(RANK)/RANK ligand/osteoprotegerin clinical implications. J Clin Endocrinol Metab 92: 4514-45121.
7. Cristenson RH, 1997 Biochemical markers of bone metabolism: an overview. Clin Biochem 30: 573-593.
8. Meunier P, Aaron J, Edouard C, et al, 1971 Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies. Clin Orthop Relat Res 80: 147-154.
9. Savopoulos Ch, Dokos CH, Kaiafa GET, et al, 2011 Adipogenesis and osteoblastogenesis: trans-differentiation in the pathophysiology of bone disorders. Hippokratia 15: 18-21.
10. Song C, Guo Z, Ma Q, et al, 2003 Simvastatin induces osteoblastic differentiation and inhibits adipocytic differentiation in mouse bone marrow stromal cells. Biochem Biophys Res Commun 308: 458-462.
11. Nuttall ME, Gimble JM, 2004 Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. Curr Opin Pharmacol 4: 290-294.
12. Van Beek E, Pieterman E, Cohen L, et al, 1999 Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing biphosphonates. Biochem Biophys Res Commun 264: 108-111.
13. Cruz AC, Gruber LB, 2002 Statins and osteoporosis: can these lipid-lowering drugs also bolster bones? Cleve Clin J Med 69: 277-288.
14. Papapoulos SE, 2011 Use of biphosphonates in the management of postmenopausal osteoporosis. Ann N Y Acad Sci 1218: 15-32.
15. Rakel A, Boucher A, Ste-Marie LG, 2011 Role of zoledronic acid in the prevention and treatment of osteoporosis. Clin Interv Aging 6: 89-99.
16. Jakob F, Oertel H, Lanqdahl B, et al, 2012 Effects of terparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-months results from the European Forsteo Observational study. Eur J Endocrinol 166: 87-97, Epub 2011 Nov 2.
17. Gallagher JC, Levine JP, 2011 Preventing osteoporosis in symptomatic postmenopausal women. Menopause 18: 109-118.
18. Bhalla AK, 2010 Management of osteoporosis in a premenopausal women. Best Pract Res Clin Rheumatol 24: 313-327.
19. De Nijs RN, Jacobs JW, Alqra A, et al, 2004, Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with metaanalysis of randomized controlled trials including organtransplantation studies. Osteoporos Int 15: 589-602.
20. Cesare R, Napolitano C, Lozzino M, 2010, Strontium ranelate in postmenopausal osteoporosis treatment: a critical appraisal. Int J Womens Health 2: 1-6.
21. Hatzitolios AI, Athyros VG, Karagiannis A, et al, 2009 IMPROVE Collaborative Group Implementation of strategy for the management of overt dyslipidemia: the IMPROVE-dyslipidemia study. Int J Cardiol 134: 322-329.
22. Ellsworth JA, Witt MD, Dugdale D, et al, Medical Drug Reference. Philadelphia: Elsevier Mosby, 2007.
23. Hmelin BA, Turgeon J, 1998 Hydrophilicity/lipophlicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 19: 26-37.
24. Brunton L, Lazo J. Goodman, et al, 2005 The pharmacological basis of therapeutics. McGraw-Hill.
25. Yeung CA, Tsao P, 2002 Statin therapy: beyond cholesterol lowering and antiinflamantory effects. Circulation 105: 2937-2938.
26. Srivastava T, Haney CJ, Alon US, 2009 Atorvastatin May Have No Effect on Acute Phase Reaction in Children After Intravenous Bisphosphonate Infusion. J Bone Miner Res 24: 334-337.
27. Liao KJ, 2004 Statin therapy: having the good without the bad. Hypertension 43: 1171-1172.
28. Hofbauer LC, Brueck CC, Shanahan CM, et al, 2007 Vascular calcification and osteoporosis-from clinical observation towards molecular undestanding. Osteoporos Int 18: 251-259.
29. Bagger YZ, Rasmussen HB, Alexandersen P, et al, 2007 PERF Study Group. Links between cardiovascular disease and osteoporosis in postmenopausal women: serum lipids or atherosclerosis per se? Osteoporos Int 18: 505-512.
30. Mundy G, Garrett R, Harris S, et al, 1999 Stimulation of bone formation in vitro and in rodents by statins. Science 286: 1946-1949.
31. Saraf SK, Singh A, Garbyal RS, et al, 2007 Effect of simvastatin on fracture healing--an experimental study. Indian J Exp Biol 454: 444-4449.
32. Wang JW, Xu SW, Yang DS, et al, 2007 Locally applied simvastatin promotes fracture healing in ovariectomized rat. Osteoporos Int 18:1641-1650.
33. Nyan M, Sato D, Oda M, et al, 2007 Bone Formation with the Combination of Simvastatin and Calcium. Sulfate in Critical-Sized Rat Calvarial Defect. J Pharmacol Sci 104: 384-386.
34. Skoglund B, Aspenberg P, 2007 Locally applied Simvastatin improves fracture healing in mice. BMC Musculoskelet Disord 8: 98.
35. Du Z, Chen J, Yan F, et al, 2009 Effects of Simvastatin on bone healing around titanium implants in osteoporotic rats. Clin. Oral Implants Res 20: 145-150.
36. Funk JL, Chen J, Downey KJ, et al, 2008 Bone Protective Effect of Simvastatin in Experimental Arthritis. J Rheumatol 35: 1083-1091.
37. Pengde K, Fuxing P, Bin S, et al, 2008 Lovastatin inhibits adipogenesis and prevents osteonecrosis in steroid-treated rabbits. Joint Bone Spine 75: 696-701.
38. Gutierrez GE, Edwards JR, Garrett IR, et al, 2008 Transdermal Lovastatin Enhances Fracture Repair in Rats. J Bone Miner Res 23: 1722-1730.
39. Kaji H, Naito J, Inoue Y, et al, 2008 Statin suppresses apoptosis in osteoblastic cells: role of transforming growth factor-beta-Smad3 pathway. Horm Metab Res 40: 746-751.
40. Alam S, Ueki K, Nakagawa K, et al, 2009 Statin-induced bone morphogenetic protein (BMP) 2 expression during bone regeneration: an immunohistochemical study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 107: 22-29.
41. Uyar Y, Baytur Y, Inceboz U, et al, 2009 Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats. Maturitas 63: 261-267.
42. Hanayama R, Shimizu H, Nakagami H, et al, 2009 Fluvastatin improves osteoporosis in fructose-fed insulin resistant model rats through blockade of the classical mevalonate pathway and antioxidant action. Int J Mol Med 23: 581-588.
43. Ayukawa Y, Yasukawa E, Moriyama Y, et al, 2009 Local application of statin promotes bone repair through the suppression of osteoclasts and the enhancement of osteoblasts at bone-healing sites in rats. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 107: 336-342.
44. Ho ML, Chen YH, Liao HJ, et al, 2009 Simvastatin increases osteoblasts and osteogenic proteins in ovariectomized rats. Eur J Clin Invest 39: 296-303.
45. Pauly S., Luttosch F, Morawski M, et al, 2009 Simvastatin locally applied from a biodegradable coating of osteosynthetic implants improves fracture healing comparable to BMP-2 application. Bone 45: 505-511.
46. Liu C, Wu Z, Sun HC, 2009 The Effect of Simvastatin on mRNA Expression of Transforming Growth Factor-β1. Bone Morphogenetic Protein-2 and Vascular Endothelial Growth Factor in Tooth Extraction Socket Int J Oral Sci 1: 90-98.
47. Chen SH, Chou FF, Ko JY, 2010 The Use of Simvastatin with Aromasin in an Ovariectomized Rat Model: Effects on the Skeletal System. Chang Gung Med J 33: 509-514.
48. Nyan M, Sato D, Kihara H, et al, 2009 Effects of the combination with alpha-tricalcium phosphate and simvastatin on bone regeneration. Clin Oral Implants Res 20: 280-287.
49. Wang W, Nyman JS, Moss HE, et al, 2010 Local Low-Dose Lovastatin Delivery Improves the Bone-Healing Defect Caused by Nf1 Loss of Function in Osteoblasts. J Bone Miner Res 25: 1658-1667.
50. Goes P, Lima AP, Melo IM, et al, 2010 Effect of Atorvastatin in radiographic density on alveolar bone loss in wistar rats. Braz Dent J 21: 193-198.
51. Lima CE, Calixto JC, Anbinder AR, 2011 Influence of the association between simvastatin and demineralized bovine bone matrix on bone repair in rats. Braz Oral Res 25: 42-48.
52. Hughes A, Rogers MJ, Idris AI, et al, 2007 A Comparison between the Effects of Hydrophobic andHydrophilic Statins on Osteoclast Function In Vitro and Ovariectomy-Induced Bone Loss In Vivo. Calcif Tissue Int 81:403-413.
53. Ruiz-Gaspa S, Nogues X, Enjuanes A, et al, 2007 Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures. J Cell Biochem 101: 1430-1438.
54. Ahn KS, Sethi G, Chaturvedi MM, et al, 2008 Simvastatin. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of NF-kappaB pathway. Int J Cancer 123: 1733-1740.
55. Yamashita M, Otsuka F, Mukai T, et al, 2008 Simvastatin antagonizes tumor necrosis factor-a inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/ Rho-mitogen-activated protein kinase pathway. J Endocrinol 196: 601-613.
56. Monjo M, Rubert M, Ellingsen JE, et al, 2010 Rosuvastatin promotes osteoblast differentiation and regulates SLCO1A1 transporter gene expression in MC3T3-E1 cells. Cell Physiol Biochem 26: 647-656.
57. Yamashita M, Otsuka F, Mukai T, et al, 2010 Simvastatin inhibits osteoclast differentiation induced by bone morphogeneticprotein-2 and RANKL through regulating MAPK, AKT and Src signaling Regulatory Peptides 162: 99-108.
58. Chen PY, Sun JS, Tsuang YH, et al, 2010 Simvastatin promotes osteoblast viability and differentiation via Ras/Smad/Erk/BMP-2 signaling pathway. Nutr Res 30: 191-199.
59. Zhou Y, Ni Y, Liu Y, et al, 2010 The role of simvastatin in the osteogenesis of injectable tissue-engineered bone based on human adipose-derived stromal cells and platelet-rich plasma. Biomaterials 31: 5325-5335.
60. Pagkalos J, Cha JM, Kang Y, et al, 2010 Simvastatin induces osteogenic differentiation of murine embryonic stem cells. J Bone Miner Res, 25: 2470-2478.
61. Uzzan B, Cohen R, Nicolas P, et al, 2007 Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone 40: 1581-1587.
62. Uysal AR, Delibasi T, Erdogan MF, et al, 2007 Effect of simvastatin use on bone mineral density in women with type 2 diabetes. Endocr Pract 13: 114-116.
63. Majima T, Komatsu Y, Fukao A, et al, 2007 Short term effects of atorvastatin on bone turnover in male patients with hypercholesterolemia. Endocr J 54: 145-151.
64. Majima T, Shimatsu A, Komatsu Y, et al, 2007 Shortterm effects of pitavastatin on biochemical markers of bone turnover in patients with hypercholesterolemia. Intern Med, 46: 1967-1973.
65. Safaei H, Janghorbani M, Aminorroaya A, et al, 2007 Lovastatin effects on bone mineral density in postmenopausal women with type 2 diabetes mellitus. Acta Diabetol 44: 76-82.
66. Bone HG, Kiel DP, Lindsay RS, et al, 2007 Effects of Atorvastatin on Bone in Postmenopausal Women with Dyslipidemia: A Double-Blind, Placebo-Controlled, Dose-Ranging Trial. J Clin Endocrinol Metab 92: 4671-4677.
67. Pérez-Castrillón JL, Vega G, Abad L, et al, 2008 Effect of the TNFalpha-308 G/A polymorphism on the changes produced by atorvastatin in bone mineral density in patients with acute coronary syndrome. Ann Nutr Metab 53: 117-121.
68. Patil S, Holt G, Raby N, et al, 2009 Prospective, double blind, randomized, controlled trial of simvastatin in human fracture healing. J Orthop Res 27: 281-285.
69. Yavuz B, Ertugrul DT, Cil H, et al, 2009 Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins? Cardiovasc Drugs Ther 23: 295-299.
70. Kanazawa I, Yamaguchi T, Yamauchi M, et al, 2009 Rosuvastatin Increased Serum Osteocalcin Levels Independent of Its Serum Cholesterol-Lowering Effect in Patients with Type 2 Diabetes and Hypercholesterolemia. Intern Med 48: 1869-1873.
71. Chuengsamarn S, Rattanamongkoulgul S, Suwanwalaikorn S, et al, 2010 Effects of statins vs. non-statin lipidlowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia. Bone 46: 1011-1015.
72. Bauer DC, Mundy GR, Jamal SA, et al, 2004 Use of Statins and Fracture. Arch Intern Med 164: 146-152.